Life
Science

Physics & Engineering

Sortieren nach: Datum | Licensing Manager

Es wurden 15 Technologieangebote gefunden

Novel Screening Method for Agents suitable for Therapy of Alzheimer´s Disease

28.10.2011 | Ref.Nr. 07081

Life Science › Pharma&Biotech

Technology
We offer a screening method that allows the detection of novel drug candidates for the prophylaxis and causative therapy of Alzheimer’s Disease.

The identified drugs influence the substrat-enzyme interaction between amyloid precursor protein (APP) and gamma-secretase in a way that less Amyloid-β-peptide (Aβ42) is produced. Furthermore they have the ability to bind selectively and with high affinity the APP-GxxxG-motif and can pass the blood-brain barrier. It was shown that a drug capable of binding the APP GxxxG motif is weakening or inhibiting the dimerization of the APP trans-membrane sequence, leading to a decreased generation of Aβ42.

IP Rights
EP patent application was filed in November 2007.
PCT patent application was filed in November 2008.
US application was filed in April 2010.

Origin
Freie Universiät Berlin

Application Area:

Drug screening

Development Stage: Product

Schlagworte: Alzheimer Disease, Drug screening,

Weitere Kategorien: Diagnostics, Life Science, Research Tools, Pharma & Biotech

Licensing Manager: Rafaela Kunz

T +49 30 2125 4825

F +49 30 2125 4822

rafaela.kunz@ipal.de

Suitable Industry: Pharmaceuticals, Research & Development

Benefits:

Reliable, rapid, and easy screening assay for the identification of novel drug candidates
Applicable to blood samples

Assay for the Diagnosis of Alzheimer’s Disease based on the Determination of the Ratio of Aß38:Aß42

28.10.2011 | Ref.Nr. 06021

Download as PDF PDF Download Share

Life Science › Pharma&Biotech

Backgorund
Processing of the amyloid precursor protein (APP) by ß-and γ -secretases leads to the generation of amyloid-ß (Aß) peptides, which are the toxic agents in the pathogenesis of Alzheimer`s Disease. γ –secretase cleaves at variable sites producing Aß peptides with different C-termini, of which particularly Aß42 contributes to cytotoxicity and amyloid accumulation in Alzheimer Disease.

We discovered that dimerization of the APP trans-membrane sequence is mediated by glycine residues G29 and G33 of the three consecutive GxxxG motifs promoting helix-helix interactions. Mutations at the glycine positions attenuate the TMS dimerization strength and specifically reduce generation of Aß42. The level of reduced Aß42 is counterbalanced by increased Aß38, whereas the level of Aß40 remains unaffected.

Technology
We offer a novel assay for the diagnosis of early and late stages of Alzheimer’s Disease. The assay is very easy to use and allows a rapid and reliable detection of Aß38:Aß42. The ratio is used to make the diagnosis.

IP Rights
European Patent application was filed in June 2006.
PCT application was filed in April 2007.
Patent applications were filed in US, JP, IN, CN, CA, FR, GB, IT, ES, DE.

Origin
Freie Universität Berlin

Application Area:

Diagnosis of Alzheimer disease at all stages

Development Stage: Product

Schlagworte: Alzheimer diagnosis, Assay, Aß38, Aß42, Better early diagnosis,

Weitere Kategorien: Diagnostics, Life Science, Research Tools, Pharma & Biotech

Licensing Manager: Rafaela Kunz

T +49 30 2125 4825

F +49 30 2125 4822

rafaela.kunz@ipal.de

Suitable Industry: Diagnostics, Pharmaceuticals

Benefits:

Suitable for diagnosing Alzheimer at early stage of disease
Reliable, easy, and rapid diagnosis
Screening of blood samples

Peptides for Diagnosis and Therapy of Celery Allergy and of Hazelnut Allergy

10.11.2010 | Ref.Nr. 10048

Download as PDF PDF Download Share

Life Science › Diagnostics

Novel linear IgE-binding peptide epitopes of the major celery allergen api g1 have been identified which are suitable for the diagnosis and therapy of celery allergy. The peptide epitopes can also serve as a basis for the detection of api g1 allergens in food and other products. Based on the novel peptides, a high specific assay was developed which allows to distinguish between celery allergic patients and healthy individuals.

Celery is a frequent cause of food allergy in pollen-sensitized patients and may induce severe allergic reactions. Allergic reactions against celery are of major clinical relevance due to celery's wide presence in convenience foods and spice. Approximately 3% - 4% of the European or American population and 5% of young children are affected by immunoglobulin E (IgE) mediated food allergy; 30% of them are sensitized to celery. The symptoms ranging from mild oral pruritus to a possible life-threatening anaphylactic shock.

IP Rights
An EP application was filed in July 2010.

Origin
The invention was made at the Charité – Universitätsmedizin Berlin.

Application Area:

Pharma, Diagnostic, Food analytic

Development Stage: Pilot study, in vitro

Type of Collaboration: Licence

Schlagworte: Allergen, Allergy, Celery, Diagnosis, Food, Hazelnut, Peptide, Therapy,

Weitere Kategorien: Diagnostics, Immunology & Infection, Nutrition, Pharma & Biotech

Licensing Manager: Dr. Bettina Büttner

T +49 30 2125 4835

F +49 30 2125 4822

bettina.buettner@ipal.de

Market Potential: Worldwide

Benefits:

Allows a specific and fast identification of the api 1g allergen in celery allergic patients
More reliable results compared to PCR- or state of the art- IgE-detection approaches are supposed
Peptide is suitable for chip applications and automatable methods
The novel peptides can be used for the desensitization of patients (Immunotherapy)

Aptamers for Treatment and Diagnosis of Autoantibody Based Dilated Cardiomyopathy

28.07.2010 | Ref.Nr. 09014

Download as PDF PDF Download Share

Life Science › Pharma&Biotech

We offer novel high affinity aptamers which inhibit the agonistic effect of autoantibodies specific for the second extracellular loop of human beta1-adrenergic receptors. Antibodies to the beta1-adrenergic receptor are detected in approximately 70% of idiopathic dilated cardiomyopathy patients and in nearly 100% of patients with Chagas’ cardiomyopathy and peripartum cardiomyopathy.

The typical characteristics of these heart muscle disorders are ventricle enlargement and the inability to pump enough blood for the body‘s needs and finally severe heart failure. For idiopathic dilated cardiomyopathy, the prevalence is 36 cases per 100,000 people and the incidence is 1–2 cases per 100,000 people per year, whereas for Chagas’ cardiomyopathy (based on the whole population of Latin America) the prevalence is 1000 cases per 100,000 people and the incidence is 10 cases per 100,000 people per year. The incidence of peripartum cardiomyopathy shows regional differences from 1 in 300 live births in Haiti to 1 in 1300-4000 live births in the US. The novel aptamers strongly inhibit the agonistic effect of beta1-adrenergic receptor-directed autoantibodies isolated from patients with idiopatic dilated cardiomyopathy, Chagas’ cardiomyopathy and peripartum cardiomyopathy, as demonstrated in a bioassay analyzing the beating frequency of rat cardiomyocytes. The specificity of the new aptamers to the autoantibodies relevant for the indicated cardiomyopathies has potential in the development of valuable new agents for diagnostic and therapeutic applications.

IP Rights
An EP application was filed on 29 June, 2010.

Origin
• Charité – Universitätsmedizin Berlin
• Max-Delbrück –Centrum für Molekulare Medizin Berlin-Buch
• Aptares AG

Application Area:

Pharma, Diagnostics

Development Stage: In vitro

Type of Collaboration: License

Schlagworte: Aptamer, Auto-Antibodies, Beta1-Adrenergic Receptor, Cardiomyopathy, Diagnostic, Dilated Cardiomyopathy,

Weitere Kategorien: Cardiology, Diagnostics, Life Science, Pharma & Biotech

Licensing Manager: Dr. Bettina Büttner

T +49 30 2125 4835

F +49 30 2125 4822

bettina.buettner@ipal.de

Suitable Industry: Pharma, Diagnostic

Market Potential: Worldwide

Benefits:

Possible new therapeutic applications in idiopathic dilated cardiomyopathy, Chagas’ cardiomyopathy and peripartum cardiomyopathy.
Very effective treatment options
Treatment is presumably associated with low side-effects.
The aptamers shows IC50 values of 100 nM or less in a rat cardiomyocyte beating assay (the antibody-mediated beating frequency increase is normalized).
The aptamers are also suitable as binders for the pathogenic autoantibodies in apheresis: an alternative to the costly and risky apheresis based on immunoadsorption.
Possible application: the diagnosis of autoantibody-based cardiomyopathies
The aptamers have promising advantages:
- Production is fast and cheap
- A wide variety of chemical modifications is possible
- The kinetic parameters can be changed on demand
- High affinity and specificity
- Aptamer activity can be controlled by the application of antidotes

In situ characterization of nanoparticles

19.03.2010 | Ref.Nr. 08057

Download as PDF PDF Download Share

Physics&Engineering

We offer a technology for in situ characterization of nanoparticles, wherein the nanoparticles are first fractionated depending on their particle size and are then analyzed via online coupling of asymmetrical flow field-flow fractionation (A4F) with small-angle X-ray scattering (SAXS). The analysis by SAXS focuses X-rays onto the nanoparticles to be analyzed by means of a slit collimator, and analyzing the nanoparticles using a detector/sample distance of less than 50 cm.

IP Rights
German Patent DE 10 2008 024 739
PCT Patent Application WO2009141370 A2

Origin
Bundesanstalt für Materialforschung und –prüfung (BAM), Germany

Application Area:

Nanotechnology, Analytical Methods, Pharmaceutical

Development Stage: Demonstration

Type of Collaboration: License, Cooperation

Schlagworte: In Situ Characterisation, Nanoparticles, Small-Angle, X-ray,

Weitere Kategorien: Diagnostics, Pharma & Biotech, Physics & Engineering

Licensing Manager: Dr. Kirk Haselton

T +49 30 2125 4842

F +49 30 2125 4822

kirk.haselton@ipal.de

Market Potential: Worldwide

Benefits:

A4F-SAXS coupling is recommended as a routine method for analysis of dispersed nanoparticles with sizes in the range of 1-100 nm. It allows a fast and quantitative comparison of different batches without the need for sample preparation.

A4F-SAXS coupling is possible with reasonable resolution using commercial X-ray sources. The demonstrated time-saving determination of size distributions provides distinct analytical advantage, particularly when particle size distribution cannot be determined with other methods, such as TEM18 and DLS (Dynamic Light Scattering).

Polyglycerin – PEG-drug conjugates

05.01.2010 | Ref.Nr. 09059

Download as PDF PDF Download Share

Life Science › Pharma&Biotech › Drug delivery

A novel drug polymer conjugate consisting of a dendritic polyglycerin (PG) core of 3-5 or more glycerol units and a polyethylene glycol shell has been developed. The pharmaceutically or diagnostically compound is covalently bound to a glycerol unit through a cleavable linker (and optionally an additional spacer). Dependently on the used linker, the compound can be cleaved physically or chemically e.g. by light, heat, or by hydrolysis, pH-dependent cleavage or cleavage by enzymes. As there are multiple glycerol units, more than one binding site exists, so that more than one active compound can be coupled to the same carrier molecule. Moreover, one carrier molecule also enables the loading of different pharmaceutically compounds (combinational therapy).

These carriers are suitable for conjugation of various drug agents or diagnostically compounds such as e.g. cytostatic agents, cytokines, immunosuppressants, virostatics, radioactive agents, light-emitting or light absorbing substance, which allows the application in therapies of various diseases. The polymer drug conjugate may be in any form suitable for the patient, for example in an injectable form, as a tablette or a capsule, or as composition for inhalation.

IP Rights
A European patent application has been filed on February, 6, 2009. International patent application (PCT) has been filed on March, 31, 2009.

Origin
The invention was made at the Freie Universität Berlin and the KTB
Tumorforschungsgesellschaft mbH Freiburg.

Application Area:

Pharma, Diagnostic

Development Stage: In vivo test (xenograft)

Type of Collaboration: License

Schlagworte: Cleavable Linker, Conjugate, Dendritic, Drug agent, Drug Polymer, Glycerol, Polyglycerin,

Weitere Kategorien: Diagnostics, Life Science, Pharma & Biotech, Drug delivery

Licensing Manager: Dr. Bettina Büttner

T +49 30 2125 4835

F +49 30 2125 4822

bettina.buettner@ipal.de

Market Potential: Worldwide

Benefits:

Carrier allows high loading with active compounds due to multiple binding sites
Design of prodrugs comprising advantageous combination of different pharmaceutically active compounds –> individualized modes of treatment
Dendritic polyglycerols can be functionalized with various reactive groups
PG-drug conjugate preparation in three steps - Shown with the cytostatic agent doxorubicin (derivatives) and the folic acid antagonist methotrexate
pH stability studies (cleavage studies) with four Doxorubicin conjugates; Cytotoxity tests in two human tumor cell lines
Cleavage study of PG-Phe-Lys-PABC-Doxorubicin with cathepsin B
Successfull in vivo studies with four Doxorubicin conjugates in the ovarian carcinoma A2780 xenograft model (mouse) -> tumor growth inhibition

Nucleic Fluorescent Probes for the Specific Detection of Single Base Alterations

05.01.2010 | Ref.Nr. 09060

Download as PDF PDF Download Share

Life Science

The present invention relates to forced intercalation probes (FIT-probes) based on nucleoside analogues with fluorescent artificial nucleobases. Thereby the nucleoside analogue is incorporated into DNA or RNA in the place of a single native base.

As such, FIT-probes may be employed in a large number of applications including genetic diagnostics, disease predisposition, pharmacogenetics and pathogen detection. The FIT-probes exhibit a simplistic mode of action and are able to detect single base alteration. They further possess few design constraints and show melting peak data which can be interpreted easily. The assay has been demonstrated to function efficiently directly from samples without prior purification of nucleic acids making the probe technology suitable for point-of-care diagnostics.

IP Rights
An European application was filed on September 8th, 2009.

Origin
The technology was developed at the Humboldt-Universität Berlin, Germany.

Application Area:

Diagnostics, Molecular Biology

Development Stage: Product, Proof of Concept

Type of Collaboration: License

Schlagworte: Disease, DNA, FIT Probes, Fluorescent, Genetic, Nucleoside, Pathogen detection, RNA, Single Base Alteration Detection,

Weitere Kategorien: Diagnostics, Life Science

Licensing Manager: Dr. Janin Hofmann

T +49 30 2125 4828

F +49 30 2125 4822

janin.hofmann@ipal.de

Market Potential: Worldwide

Benefits:

More specific and sensitive than common PNA probes
First time manufacturing of DNA probes
Abdication of linker enhances dye properties
Enhanced sensitivity as probes differ between correct and incorrect hybridization
Application at room temperature
Wide range of application
DNA probes allow detection in living cells by Fluorescence in situ hybridization (FISH)
Enzyme activity is not influenced
Inexpensive production

A Method for Restoring BMP-Receptor Signaling in a Cell

05.01.2010 | Ref.Nr. 07154

Download as PDF PDF Download Share

Life Science

BMP signaling is essential for developmental processes and tissue homeostasis and therefore highly regulated. Defects in BMP signaling can cause different disease as for example pulmonary arterial hypertension.

The inventors found that cGKI interacts with BRII and enhances the BMP receptor Smad signaling as a adaptor protein via a novel mechanism. The receptor regulated Smad proteins (R-Smad), Smads 1 and 5, are intracellular mediators of BMP signaling. These proteins translocate together with Smad4 to the nucleus.

Their they modulate transcription by binding to specific sequences on the promoters of target genes. It is suggested that cGKI stimulates Smad mediated BMP2 signaling and regulates gene expression of a transcriptional co-factor for Smads (Id1).

The increase in cGKI expression can compensate the defective BMP signaling cascade originating from a BRII mutant and restore the signaling pathway. The novel cGKI-based pharmaceuticals can be used to treat a cell, tissue or an organism with a disease or a condition that is associated with impeded or interrupted BMP-receptor signaling, insofar as the activity of cGKI is increased in the cell, tissue or organ to be treated

IP Rights
A PCT Application was filed on February 27, 2009 claiming priority of a European Patent Application filed on February 27, 2008.

Origin
The method was developed at the Freie Universität Berlin.

Application Area:

Pharma

Development Stage: In vivo

Type of Collaboration: License

Schlagworte: BMP, Cell, Organ, Protein, Receptor, Smad, Tissue,

Weitere Kategorien: Cardiology, Diagnostics, Life Science

Licensing Manager: Rafaela Kunz

T +49 30 2125 4825

F +49 30 2125 4822

rafaela.kunz@ipal.de

Market Potential: Worldwide

Benefits:

Method offers a additive for restoring or enhancing BMP receptor signaling
Knowing the meaning of an enhanced cGKI activity allows for targeted production of pharmaceuticals with a high cGKI fraction
Use BMP receptors to screen for substances for their cGKI activity
Use cGKI as detector to find receptors they can bind to and identifying & isolating the related proteins
cGKI can be used to transcriptional activate genes that have a BMP response element

A Stable Cell Line that is Inducible to Express hsTRPM2

29.10.2009 | Ref.Nr. 08135

Download as PDF PDF Download Share

Life Science › Pharma&Biotech

The transient receptor potential melastanin-related 2 (TRPM2) channel functions as a central connective element between oxidative stress and intracellular calcium homeostasis. In contrast to other TRP-cation channels, TRPM2 has its own specific pharmacology that cannot be inhibited by known, non-selective, inorganic TRP-cation channel blockers. Therefore a method is needed that enables an effective screening for new TRPM2 blockers.

To meet the needs the inventors established a stable, TRPM2-expressing mammal cell line that expresses the cation channel TRPM2 in an inducible way. Thus the modified cell line offers a methodology for the identification of new and improved TRPM-2 channel inhibitors and activators. The cell line used for TRPM2 cloning is the commercially available Flip-In T-Rex 293 cell line.

Origin
The cell line was created at the Charité – Universitätsmedizin Berlin.

Application Area:

Pharma

Development Stage: Product

Type of Collaboration: License

Schlagworte: Calcium Homeostasis, Cell, Oxidative Stress, Pharmacology, TRPM2,

Weitere Kategorien: Diagnostics, Life Science, CNS & Neurology, CNS & Neurology, Pharma & Biotech

Licensing Manager: Rafaela Kunz

T +49 30 2125 4825

F +49 30 2125 4822

rafaela.kunz@ipal.de

Market Potential: Worldwide

Benefits:

Stable cell line
TRPM2 expression can be controlled and induced
Allows effective screening for TRPM2 blockers
Wide application field (Identification of activators and inhibitors of the TRP-cation channels, Identification of TRPM2-Targets that might be useful as: Asthma therapeutics, Immunotherapeutics, Therapeutics in the therapy of neurodegenerative diseases (e.g. Multiple Sclerosis, Alzheimer’s Disease, Parkinson's Disease)

Functionalized Nanoparticles as Novel Anti-Inflammatory Therapeutics

22.10.2009 | Ref.Nr. 07089

Download as PDF PDF Download Share

Life Science › Pharma&Biotech

Leukocyte-endothelial cell interaction plays an important role in acute and chronic inflammatory processes. The involvement of the cell adhesion molecules E-, P- and Lselectin and their ligands makes them to suitable targets for diagnosis and therapy.

High-affinity inhibitors of selectin-ligand interaction are offered, suitable for the treatment of a wide range of inflammatory diseases, such as Rheumatoid Arthritis and other autoimmune disorders. The novel functionalized gold nanoparticles exhibit excellent selectin-inhibitory capacity with IC50 in the lower picomolar range and a far higher affinity for selectins than any other known selectin-inhibitor.

Thus, the nanoparticles could provide a potent way of treating a variety of inflammatory diseases by an efficient inhibition of the selectin-ligand binding, which in turn mediate the interaction between leukocytes and the endothelium.

IP Rights
PCT applications were filed in September 2008 (with priority of 2007) and May 2009 (with priority of 2008).

Origin
The invention was made at Freie Universität and Charité - Universitätsmedizin in Berlin, Germany.

Application Area:

Pharma

Development Stage: In vitro

Type of Collaboration: License

Schlagworte: Cell, Gold-Colloids, Inflammatory Diseases, Nanoparticle, Selectin Inhibitor, Treatment,

Weitere Kategorien: Diagnostics, Life Science, Immunology & Infection, Immunology & Infection, Pharma & Biotech

Licensing Manager: Rafaela Kunz

T +49 30 2125 4825

F +49 30 2125 4822

rafaela.kunz@ipal.de

Market Potential: Worldwide

Benefits:

Until now, no approved selectin-inhibitors available.
Functionalized nanoparticles, in particular with a core of gold, have so far been mainly used in diagnostic and imaging applications
Potential therapeutic application of the developed nanoparticles, due to their high affinity and low IC50 values.
Easy synthesis and high stability in physiological environments.